Yuan Zhi
Stock Analyst at B. Riley Securities
(4.51)
# 1,084
Out of 4,703 analysts
136
Total ratings
43.3%
Success rate
20.2%
Average return
Main Sectors:
Stocks Rated by Yuan Zhi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NUTX Nutex Health | Maintained: Buy | $325 | $193.24 | +68.18% | 1 | Sep 4, 2026 | |
| LNTH Lantheus Holdings | Downgraded: Hold | $129 → $105 | $100.97 | +4.39% | 28 | Aug 18, 2026 | |
| HYPR Hyperfine | Maintained: Buy | $2 → $1.6 | $0.8133 | +96.73% | 9 | Aug 10, 2026 | |
| STLN Starling Oncology | Maintained: Buy | $6 → $11 | $5.93 | +85.50% | 3 | Aug 7, 2026 | |
| MIR Mirion Technologies | Maintained: Buy | $29 | $16.93 | +71.29% | 11 | Jul 30, 2026 | |
| LYEL Lyell Immunopharma | Initiated Coverage: Buy | $44 | $14.37 | +206.19% | 1 | Jul 22, 2026 | |
| WHWK Whitehawk Therapeutics | Initiated Coverage: Buy | $10 | $4.60 | +117.39% | 1 | Jun 25, 2026 | |
| TNGX Tango Therapeutics | Rated: Buy | $21 → $35 | $22.52 | +55.42% | 7 | Jun 9, 2026 | |
| RDNT RadNet | Rated: Buy | $87 → $83 | $73.71 | +12.60% | 6 | May 1, 2026 | |
| SRTA Strata Critical Medical | Initiated Coverage: Buy | $8 | $5.32 | +50.38% | 1 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $11 → $13 | $3.13 | +315.34% | 13 | Mar 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $4.92 | +103.25% | 2 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $13 → $16 | $2.08 | +669.23% | 6 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 → $3 | $0.3501 | n/a | 3 | Oct 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $16 → $2 | $1.03 | n/a | 13 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $19 → $15 | $15.81 | n/a | 14 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $79 | $31.33 | n/a | 12 | Feb 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $34 | $35.25 | n/a | 5 | Jan 9, 2023 |
Nutex Health
Sep 4, 2026
Maintained: Buy
Price Target: $325
Current: $193.24
Upside: +68.18%
Lantheus Holdings
Aug 18, 2026
Downgraded: Hold
Price Target: $129 → $105
Current: $100.97
Upside: +4.39%
Hyperfine
Aug 10, 2026
Maintained: Buy
Price Target: $2 → $1.6
Current: $0.8133
Upside: +96.73%
Starling Oncology
Aug 7, 2026
Maintained: Buy
Price Target: $6 → $11
Current: $5.93
Upside: +85.50%
Mirion Technologies
Jul 30, 2026
Maintained: Buy
Price Target: $29
Current: $16.93
Upside: +71.29%
Lyell Immunopharma
Jul 22, 2026
Initiated Coverage: Buy
Price Target: $44
Current: $14.37
Upside: +206.19%
Whitehawk Therapeutics
Jun 25, 2026
Initiated Coverage: Buy
Price Target: $10
Current: $4.60
Upside: +117.39%
Tango Therapeutics
Jun 9, 2026
Rated: Buy
Price Target: $21 → $35
Current: $22.52
Upside: +55.42%
RadNet
May 1, 2026
Rated: Buy
Price Target: $87 → $83
Current: $73.71
Upside: +12.60%
Strata Critical Medical
Mar 25, 2026
Initiated Coverage: Buy
Price Target: $8
Current: $5.32
Upside: +50.38%
Mar 18, 2026
Rated: Buy
Price Target: $11 → $13
Current: $3.13
Upside: +315.34%
Dec 17, 2025
Maintained: Buy
Price Target: $10
Current: $4.92
Upside: +103.25%
Dec 16, 2025
Maintained: Buy
Price Target: $13 → $16
Current: $2.08
Upside: +669.23%
Oct 2, 2024
Reiterated: Buy
Price Target: $4 → $3
Current: $0.3501
Upside: n/a
Aug 7, 2024
Downgraded: Hold
Price Target: $16 → $2
Current: $1.03
Upside: n/a
Jul 30, 2024
Upgraded: Buy
Price Target: $19 → $15
Current: $15.81
Upside: n/a
Feb 7, 2024
Reiterated: Buy
Price Target: $79
Current: $31.33
Upside: n/a
Jan 9, 2023
Maintained: Buy
Price Target: $34
Current: $35.25
Upside: n/a